StreetInsider.com News Articles

Form 4 Phio Pharmaceuticals For: Aug 19 Filed by: Plott Ronald Todd

Thu, 20 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26953473.html

Form 4 Phio Pharmaceuticals For: Aug 19 Filed by: Plott Ronald Todd

Thu, 20 Aug 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26953473.html

Form 4 Phio Pharmaceuticals For: Aug 18 Filed by: Bitterman Robert J

Wed, 19 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26949937.html

Form 4 Phio Pharmaceuticals For: Aug 18 Filed by: Bitterman Robert J

Wed, 19 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260819/26949937.html

Form ARS Phio Pharmaceuticals For: Dec 31

Fri, 14 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26930760.html

Form ARS Phio Pharmaceuticals For: Dec 31

Fri, 14 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260814/26930760.html

Form DEFA14A Phio Pharmaceuticals

Fri, 14 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26930717.html

Form DEFA14A Phio Pharmaceuticals

Fri, 14 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260814/26930717.html

Form DEF 14A Phio Pharmaceuticals For: Sep 28

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930195.html

Form DEF 14A Phio Pharmaceuticals For: Sep 28

Fri, 14 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26930195.html

Phio Pharmaceuticals receives U.S. patent allowance for PH-894

Tue, 11 Aug 2026 07:02:12 -0400

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced it has received a U.S. Notice of Allowance for a patent covering PH-894, a compound designed to selectively silence the BRD4 protein, a regulator of gene expression associated with proliferative and infectious diseases.

The allowed patent covers PH-894's chemical structure, genetic sequencing, and broad applications. The compound is part of the company's INTASYL gene-silencing platform.

"Robust intellectual property protection is a continuous focus in our development strategy to advance novel immuno-oncology therapies and maximize the long-term value of the INTASYL platform," said Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. "This patent advancement solidifies

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Tue, 11 Aug 2026 07:00:00 -0400

PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.

King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio.

The patent allowance represents a critical milestone in protecting Phio's strategic interest in the Company's INTASYL® platform. PH-894, designed to selectively silence BRD4, is a key regulator of gene expression associated with proliferative and

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Tue, 11 Aug 2026 07:00:00 -0400

PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.

Phio Pharmaceuticals Corp. (PHIO) Misses Q2 EPS by 6c

Thu, 06 Aug 2026 18:04:48 -0400

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) reported Q2 EPS of ($0.36), $0.06 worse than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Phio Pharmaceuticals Corp. (PHIO) click here.

Form 8-K Phio Pharmaceuticals For: Aug 06

Thu, 06 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26884307.html

Form 8-K Phio Pharmaceuticals For: Aug 06

Thu, 06 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26884307.html

Form 10-Q Phio Pharmaceuticals For: Jun 30

Thu, 06 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260806/26884168.html

Form 10-Q Phio Pharmaceuticals For: Jun 30

Thu, 06 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260806/26884168.html

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Strategic milestone advancements for lead clinical candidate PH-762

Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcements

King of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended June 30, 2026, and provided a business update.

"We realized significant headway on foundational building blocks advancing the PH-762 development program during the 2^nd quarter," said Robert J. Bitterman, President and CEO.

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Thu, 06 Aug 2026 16:05:00 -0400

Strategic milestone advancements for lead clinical candidate PH-762

Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcements

"We realized significant headway on foundational building blocks advancing the PH-762 development program during the 2^nd quarter," said Robert J. Bitterman, President and CEO.

Form 3 Phio Pharmaceuticals For: Jul 20 Filed by: Plott Ronald Todd

Thu, 30 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260730/26843323.html

Form 3 Phio Pharmaceuticals For: Jul 20 Filed by: Plott Ronald Todd

Thu, 30 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260730/26843323.html

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL^® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session. This release corrects the day of the week that the

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 07:00:00 -0400

Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT

"We look forward to engaging with investors at the Renmark Financial Virtual